ReNeuron Group PLC - Bridgend, Wales-based stem cell and exosomes technology company - Promotes Financial Controller John Hawkins to chief financial officer with immediate effect. Hawkins joined the company in 2014 as financial controller and was also named as the company secretary last year. Says Hawkins is an experienced finance professional with a breadth of experience gained within ‘a variety of businesses, from large PLCs to family-owned SMEs’.

ReNeuron also names Simon Dew as chief business officer, who currently is a senior healthcare executive with extensive experience in Business Development and Corporate Strategy. Most recently, he worked at biotechnology company Evox Therapeutics Ltd, where he was responsible for leading two transformational partnership deals with global pharmaceutical companies.

Chief Executive Officer Catherine Isted says: ‘[Hawkins] has been a key part of the team redefining the operational and strategic focus of the group and his extensive knowledge of the business and tireless work ethic have been invaluable especially in this period of transition. The appointment of Simon Dew as CBO will be a key role in the new ReNeuron executive team to maximise the opportunity we see ahead of us in the field and to accelerate our partnership opportunities.’

Current stock price: 26.32 pence, down 2.5%

12-month change: down 74%

Copyright 2022 Alliance News Limited. All Rights Reserved.